Login to Your Account

In The Clinic NEWS

Positive phase IIb data with MIN-101 in schizophrenia paves the way to pivotal testing and gives patients hope for their negative symptoms, Minerva Neurosciences Inc. spokesman William Boni told BioWorld Today. “I don’t want to use any words like ‘breakthrough,’” he said, because there needs to be more testing done, “but there is no effective treatment for negative symptoms at this point.”

DUBLIN – Xenikos BV is on track to complete recruitment in a phase I/II trial of T-Guard, a combination of two antibody-drug conjugates in development for treating steroid refractory graft-vs.-host disease (GvHD), in the coming months. The company expects to report survival data early next year, but, based on what it has seen so far, it is already contemplating a potentially pivotal phase II trial as its next step, which could lead to an application for conditional marketing authorization.

Seattle Genetics Inc. (Seagen) started its second-ever phase III study, pitting a CD33-targeted antibody-drug conjugate paired with widely used HMA vs. HMAs alone in older patients with newly diagnosed AML.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: